Dan Atar

Rethinking β-blockers after MI Our @NEJM Editorial integrates evidence from two recent IPD meta-analyses and outlines the emerging paradigm for β-blockade after MI. 
👉 nejm.org/doi/full/10.10… ➡️ Time for personalized secondary prevention @Borjaibanez1 @dan_atar @DLBHATTMD

CVCT stands out as a unique and most exciting “different” kind of conference where involvement across all stakeholders is key. Huge congratulations to Faiez Zannad and Javed Butler to such a great achievement. Honored to be back as faculty and to contribute to science.

At #CVCT2025 I reviewed the nonlinear basic discovery arc underlying clinical development from autologous #CDCs #postMI to #deramiocel for #Duchenne #cardiomyopathy culminating in the blockbuster #HOPE3 trial by @Capricor. Odyssean journey! @SmidtHeart @CIRMnews @CoalitionDMD

@MarbanLab @rblument1 @CIRMnews @NIH @CoalitionDMD @rrogerslab @A22002Mark @SmidtHeart My sincere congratulations. It comes just in time after your magnificent Honorary Lecture at the AHA.

A 21 year journey of invention, discovery and mechanistic investigation yields the first therapy shown to improve both heart and skeletal muscle function in #Duchenne muscular dystrophy. @CIRMnews @NIH @CoalitionDMD @rrogerslab @A22002Mark @SmidtHeart

#CVCT2025: Beta-blockers post-MI have been discussed for the last 50 years. Early trials firmly documented survival benefits, but the entire landscape has changed. Contemporary trials now provide clear answers. Join us, December 8-10, Washington DC: lnkd.in/dyg5BMwm #CVCT

And here with the registration link: ESC 365 - Are beta-blockers still indicated after myocardial infarction?   myesc.escardio.org/MyESC/s/event-…

Any HCP who is involved in post-MI care: this ESC Webinar may be of interest to you: #Oslo Center for Clinical Heart Research # Escardio webinars

@evandrofilhobr @DrPascalMeier Wonderful 👏

Great photo @DrPascalMeier

@Hragy Likewise, such a pleasure.

@dan_atar at Graz Cardiac Summit - a real pleasure to meet again:)

My @TCTMD LBT interview with @dan_atar and @Borjaibanez1 around REBOOT-CNIC and BETAMI-DANBLOCK trials @escardio ➡️ tctmd.com/videos/beyond-… @Hragy @mirvatalasnag @hvanspall @DrMarthaGulati @purviparwani @SVRaoMD @SandeepNathanMD @iamritu

Honored and humble to present the BETAMI-DANBLOCK trial on behalf of a combined Norwegian and Danish cardiovascular community. The main auditorium in Madrid was packed. lnkd.in/dinhXrWD #Oslo Center for Clinical Heart Research

#ESCCongress is almost here! Don't miss 🔥 Hot Line discussions with 💫 Dr @hvanspall & expert guests: Prof @FaiezZANNAD, Prof @dan_atar, Dr Anna Meta Dyrvig Kristensen, Prof Michael Borger, Prof Udo Bavendiek, Prof @j_rvl & Dr Julie De Backer. 🫀 Cutting-edge insights, straight from this year's conference. #ESCCongress2025 #ESC2025 #CardioEd

@Borjaibanez1 @RebootTrial @RosselloXavier @YndigegnY @S_Raposeiras @anguita_m @secardiologia @cpgale3 @JovenesSec @john_munkhaugen Thank you Prof. Chris Gale for being on our DSMB!

#ESCcongress2025 Hotine#3. Two large trials (@RebootTrial (n=8500) & betami+danblock (n=5500 together)) PLUS a metaanalysis of them focused in the subgroup of Pt with mildly reduced LVEF are presented. Stay tuned!!

🎯 Do betablockers (BB) reduce MACE after MI with LVEF >40% and no heart failure?

Exciting new clinical science coming your way at ESC. Join us on Saturday 30/8 at 11:00-12:00 CET. #Oslo Center for Clinical Heart Research

TEN HOT LINES ❤️‍🔥10 hot line sessions already released by @escardio #ESCcongress ❤️‍🔥They feature 42 major trials alongside 129 exciting additional studies ❤️‍🔥Spanish trials lead one of them, highlighitng ⬆️level of scientific research lnkd.in/d_mQCUJX @RosselloJavier #CardioX

@CMichaelGibson I’m afraid your dream bookstore place will be on a downhill slope and financially non-sustainable. Youngsters don’t read books any longer…😢

My place will have a great fireplace, comfy couches, and live music. I will paint in the back, chat with people and hear their stories. Would you come 😊

Check out our webinar on various aspects of cardio-oncology recorded yesterday in Stockholm: dagensmedisin.no/dmarena/nordic… @dan_atar @CTCPR_ @RigsHeart

En minneverdig dag den 25/4/2025 med uhyre spennende vitenskapelige diskusjoner i anledning dr. Camilla Settergren sin disputas på Karolinska instituttet. Takk for å få den ærefulle oppgaven som opponent. Gratulerer til kandidaten og hennes 4 enestående veiledere 👏🎼🥂